Mechanism and basics

retatrutide what is it

Published May 2, 2026Updated May 3, 2026Medical safety, official-source, and research-reference review

Retatrutide is an investigational triple agonist from Lilly, not an approved consumer product.

Direct answer

Retatrutide is a single investigational molecule from Lilly that activates GIP, GLP-1, and glucagon receptors. It is being studied in clinical trials and is not FDA approved.

Research context

These references frame the evidence base behind this topic. They are not medical advice, approval, or instructions for using retatrutide outside a clinical trial.

Short source quoteagonist of the GIP, GLP-1, and glucagon receptors

Jastreboff et al., NEJM 2023 retatrutide phase 2 obesity trial

This peer-reviewed phase 2 paper is the anchor for retatrutide mechanism language. It does not make retatrutide approved or publicly available.

Short source quoterandomised, double-blind, placebo and active-controlled

Rosenstock et al., Lancet 2023 retatrutide phase 2 type 2 diabetes trial

The type 2 diabetes phase 2 paper helps separate controlled clinical research from online self-use claims.

Short source quoterandomized, double-blind, placebo-controlled trial

Sanyal et al., Nature Medicine 2024 retatrutide MASLD phase 2a trial

The MASLD substudy adds peer-reviewed evidence for metabolic research context, but it is still not public-use approval.

Short source quotecombining the activity of GLP-1, GIP, and glucagon

Bossart et al., Cell Metabolism 2022 GLP-1/GIP/glucagon triagonist study

This triagonist paper supports the broader triple-agonist mechanism discussion, not claims about any unapproved product sold online.

Short source quotebiological actions, and therapeutic relevance

Baggio and Drucker, Gastroenterology 2007 biology of incretins review

This review supports mechanism explanations around GLP-1 and GIP biology without turning mechanism into treatment advice.

What to know before acting on this search

It is often discussed alongside semaglutide and tirzepatide because all relate to incretin-based metabolic treatment.
Lilly says retatrutide is not yet available for public use.
Clinical studies have reported weight and A1C outcomes, but regulatory review is still the key public-access gate.

Safety and compliance notes

The nickname GLP-3 is informal and scientifically inaccurate, according to Lilly.
Online product listings can misuse the name retatrutide.
A basic definition should always be paired with approval and safety context.

Safer next step

Read the peptide guide, GLP-3 guide, and FDA status page for the full context.

Medical disclaimer

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. Retatrutide is investigational and is not FDA approved. FDA-approved options such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.